Literature DB >> 79913

Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man?

L F Odom, C S August, J H Githens, J R Humbert, H Morse, D Peakman, B Sharma, S L Rusnak, F B Johnson.   

Abstract

Acute lymphoblastic leukaemic in two boys relapsed after engraftment of marrow from siblings identical at HLA A, B, and D loci but went into remission during subsequent graft-versus-host reactions without specific anti-leukaemia therapy. Later leukaemic relapse was primarily in extramedullary sites, with little or no involvement of bone-marrow, liver, or spleen. Cytogenetic studies in both cases showed that the relapsed leukaemic blasts were those of the recipients while marrow cells and blood lymphocytes detected during marrow remission originated from the female donors. Blood lymphocytes from one of the recepients kiled. 51Cr-labelled autologous lymphoblast. The prolonged bone-marrow remission in the face of active and even massive extramedullary leukaemia suggests a graft-versus-leukaemia reaction in these two patients.

Entities:  

Mesh:

Year:  1978        PMID: 79913     DOI: 10.1016/s0140-6736(78)92879-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  18 in total

Review 1.  Graft versus leukemia.

Authors:  A Butturini; R P Gale
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 2.  Autografting as first line treatment for chronic myeloid leukaemia.

Authors:  I O Singer; I M Franklin
Journal:  J Clin Pathol       Date:  1998-02       Impact factor: 3.411

Review 3.  Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.

Authors:  Abhinav Deol; Lawrence G Lum
Journal:  Cancer Treat Rev       Date:  2010-04-09       Impact factor: 12.111

4.  Changes in antibiotic sensitivity in strains of Staphylococcus aureus, 1952-78.

Authors:  Z A Hassam; E J Shaw; R A Shooter; D B Caro
Journal:  Br Med J       Date:  1978-08-19

Review 5.  Allogeneic stem cell transplantation for chronic myeloid leukemia.

Authors:  Jiří Pavlů; Jane F Apperley
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

6.  Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.

Authors:  David A Rizzieri; Christopher Crout; Robert Storms; Jared Golob; Gwynn D Long; Cristina Gasparetto; Keith M Sullivan; Mitchell Horwitz; John Chute; Anand S Lagoo; Ashley Morris; Anne Beaven; Yiping Yang; Bercedis Peterson; Zhiguo Li; Nelson J Chao
Journal:  Cancer Invest       Date:  2011-01       Impact factor: 2.176

Review 7.  Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.

Authors:  Arnab Ghosh; Amanda M Holland; Marcel R M van den Brink
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.

Authors:  D A Rizzieri; P Dev; G D Long; C Gasparetto; K M Sullivan; Ml Horwitz; J Chute; N J Chao
Journal:  Bone Marrow Transplant       Date:  2008-10-13       Impact factor: 5.483

Review 9.  Graft-versus-host disease, the graft-versus-leukemia effect, and mixed chimerism following nonmyeloablative stem cell transplantation.

Authors:  Shimon Slavin
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

10.  [Bone marrow transplantation for relapsed, acute leukaemia (author's transl)].

Authors:  H J Kolb; C Bender-Götze; E D Albert; R Haas; G Janka
Journal:  Klin Wochenschr       Date:  1981-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.